ELD 403
Alternative Names: ELD-403Latest Information Update: 27 Oct 2023
At a glance
- Originator Eldec Pharmaceuticals
- Class Antivirals; Peptides
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Respiratory syncytial virus infections
Most Recent Events
- 12 Sep 2023 Early research in Respiratory syncytial virus infections in USA (unspecified route), prior to September 2023 (Eldec Pharmaceuticals pipeline, September 2023)